You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer
Free
  1. Yasmine Assadipour1,
  2. Stephanie Goff2,
  3. Jessica S Crystal3,
  4. Todd D Prickett4,
  5. Jared J Gartner5,
  6. Robert Somerville6,
  7. Hui Xu6,
  8. Mary Black6,
  9. Isaac Kriley6,
  10. Paul F Robbins5,
  11. Steven A Rosenberg5 and
  12. Steven Feldman6
  1. Aff1 grid.253615.60000000419369510George Washington University Washington DC USA
  2. Aff2 grid.48336.3a0000000419368075Surgery BranchNIH/NCI Bethesda MD USA
  3. Aff3 grid.48336.3a0000000419368075Rutgers Robert Wood Johnson Medical SchoolNCI/NIH New Brunswick NJ USA
  4. Aff4 grid.48336.3a0000000419368075NCI/NIH Bethesda MD USA
  5. Aff5 grid.48336.3a0000000419368075Surgery Branch/National Cancer Institute/National Institutes of Health Bethesda MD USA
  6. Aff6 grid.48336.3a0000000419368075NIH/NCI Bethesda MD USA

https://doi.org/10.1186/2051-1426-3-S2-P284

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    A growing body of evidence suggests that successful clinical immunotherapy may depend on mutation-specific T cell responses. Using whole-exome and RNA sequencing of a resected metastatic deposit from a patient with triple-negative (ER-, PR-, Her2 non-amplified) breast cancer, we identified 72 non-synonymous mutations. Using previously published methods of autologous antigen presentation[1], we identified a novel non-synonymous mutation in a regulator of the Notch signaling pathway, RBPJ (recombination signal binding protein for immunoglobulin kappa J region), that encodes a neoantigen specifically recognized by autologous CD4+ tumor infiltrating lymphocytes. Antigen recognition was restricted by the Class II DR locus. Deep sequencing or PCR of all 16 metastases collected at autopsy revealed that the mutation was ubiquitously present in all samples. To the best of our knowledge, this represents the first report of an immunogenic mutation in breast cancer.

    References

    1. 1.↵
      1. Tran E,
      2. Turcotte S,
      3. Gros A, et al
      . Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344:641–5. doi:10.1126/science.1251102
      OpenUrlAbstract/FREE Full Text